Abstract
Bupropion major depresyon tedavisinde genel olarak güvenli ve iyi tolere
edilebilir bir seçenektir. Preklinik çalışmalarda serum transaminaz
seviyelerinde hafif ve geçici yükselmelere neden olduğu gösterilmiştir. Bu vaka
sunumunda başka bir rahatsızlığı olmayan major depresyon hastasında bupropion
kullanımından sonra gelişen ve ilaç kesilince düzelen transaminaz yükselmesi
rapor edilmektedir.
Keywords
References
- 1. Wilkes S. Bupropion. Drugs Today (Barc) 2006;42:671-81
- 2. Alvaro D, Onetti-Muda A, Moscatelli R, Attili AF. Acute cholestatic hepatitis induced by bupropion prescribed as pharmacological support to stop smoking. A case report. Dig Liver Dis 2001;33:703-6.
- 3. Tucker WE, Preclinical toxicology of bupropion, an owerview. J clin. Psychiatry 1983;44:60-2.
- 4. Oslin DW, Duffy K. The rise of serum aminotransferases in a patient treated with bupropion. J Clin Psychopharmacol 1993;13:364-5.
- 5. Khoo AL, Tham LS, Lee KH, Lim GK. Acute liver failure with concurrent bupropion and carbimazole therapy. Ann Pharmacother 2003;37: 220-3. DOI 10.1345/aph.1C159.
- 6. Bagshaw SM, Cload B, Gilmour J, Leung ST, Bowen TJ. Drug-induced rash with eosinophilia and systemic symptoms syndrome with bupropion administration. Ann Allergy Asthma Immunol 2003;90:572-5.
- 7. Hu KQ, Tiyyagura L, Kanel G, Redeker AG. Acute hepatitis induced by bupropion. Dig Dis Sci 2000;45:1872-3.
- 8. Humayun F, Shehab TM, Tworek JA, Fontana RJ: A fatal case of bupropion (Zyban) hepatotoxicity with autoimmune features: case report. J Med Case Reports 2007;1:88.
- 9. Verma S, Kaplowitz N: Diagnosis, management, and prevention of drug-induced liver injury. Gut 2009; 58:1555–64.
Abstract
Generally bupropion is considered as a safe and well-tolerated
antidepressant for the treatment of major depression. In preclinical studies,
mild and transient elevation of serum aminotransferases was observed and also phase 3 studies
revealed this increase as up to 1%. In this case report, we aimed to present a
major depression patient with asymptomatic elevation of liver enzymes after
bupropion treatment which returned to normal values after bupropion stopped.
Keywords
References
- 1. Wilkes S. Bupropion. Drugs Today (Barc) 2006;42:671-81
- 2. Alvaro D, Onetti-Muda A, Moscatelli R, Attili AF. Acute cholestatic hepatitis induced by bupropion prescribed as pharmacological support to stop smoking. A case report. Dig Liver Dis 2001;33:703-6.
- 3. Tucker WE, Preclinical toxicology of bupropion, an owerview. J clin. Psychiatry 1983;44:60-2.
- 4. Oslin DW, Duffy K. The rise of serum aminotransferases in a patient treated with bupropion. J Clin Psychopharmacol 1993;13:364-5.
- 5. Khoo AL, Tham LS, Lee KH, Lim GK. Acute liver failure with concurrent bupropion and carbimazole therapy. Ann Pharmacother 2003;37: 220-3. DOI 10.1345/aph.1C159.
- 6. Bagshaw SM, Cload B, Gilmour J, Leung ST, Bowen TJ. Drug-induced rash with eosinophilia and systemic symptoms syndrome with bupropion administration. Ann Allergy Asthma Immunol 2003;90:572-5.
- 7. Hu KQ, Tiyyagura L, Kanel G, Redeker AG. Acute hepatitis induced by bupropion. Dig Dis Sci 2000;45:1872-3.
- 8. Humayun F, Shehab TM, Tworek JA, Fontana RJ: A fatal case of bupropion (Zyban) hepatotoxicity with autoimmune features: case report. J Med Case Reports 2007;1:88.
- 9. Verma S, Kaplowitz N: Diagnosis, management, and prevention of drug-induced liver injury. Gut 2009; 58:1555–64.
Details
| Primary Language | English |
|---|---|
| Subjects | Health Care Administration |
| Journal Section | Case Report |
| Authors | |
| Publication Date | December 15, 2016 |
| Submission Date | January 6, 2018 |
| Acceptance Date | February 24, 2018 |
| Published in Issue | Year 2016 Volume: 2 Issue: 3 |
